Colleen Kusy
Stock Analyst at Baird
(0.89)
# 3,627
Out of 4,784 analysts
42
Total ratings
26.32%
Success rate
-14.81%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Colleen Kusy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OCS Oculis Holding AG | Maintains: Outperform | $37 → $41 | $19.18 | +113.76% | 4 | Mar 13, 2025 | |
| AGEN Agenus | Maintains: Neutral | $6 → $3 | $1.60 | +87.50% | 2 | Mar 12, 2025 | |
| CHRS Coherus BioSciences | Maintains: Outperform | $4 → $6 | $0.84 | +615.48% | 5 | Dec 5, 2024 | |
| ELVN Enliven Therapeutics | Maintains: Outperform | $32 → $40 | $21.07 | +89.84% | 2 | Nov 15, 2024 | |
| SYRE Spyre Therapeutics | Maintains: Outperform | $50 → $65 | $17.94 | +262.32% | 2 | Nov 13, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $92 → $55 | $24.27 | +126.62% | 10 | Nov 7, 2024 | |
| MRSN Mersana Therapeutics | Maintains: Neutral | $4 → $3 | $0.38 | +690.51% | 4 | Aug 14, 2024 | |
| OCUL Ocular Therapeutix | Maintains: Outperform | $18 → $17 | $7.58 | +124.27% | 4 | Aug 8, 2024 | |
| ORIC ORIC Pharmaceuticals | Reiterates: Outperform | $27 → $25 | $6.14 | +307.17% | 1 | Mar 12, 2024 | |
| NUVL Nuvalent | Initiates: Outperform | $105 | $73.05 | +43.74% | 1 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $255 → $210 | $4.16 | +4,948.08% | 1 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $3.56 | +855.06% | 5 | Apr 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $230 | $1.48 | +15,440.54% | 1 | Nov 2, 2021 |
Oculis Holding AG
Mar 13, 2025
Maintains: Outperform
Price Target: $37 → $41
Current: $19.18
Upside: +113.76%
Agenus
Mar 12, 2025
Maintains: Neutral
Price Target: $6 → $3
Current: $1.60
Upside: +87.50%
Coherus BioSciences
Dec 5, 2024
Maintains: Outperform
Price Target: $4 → $6
Current: $0.84
Upside: +615.48%
Enliven Therapeutics
Nov 15, 2024
Maintains: Outperform
Price Target: $32 → $40
Current: $21.07
Upside: +89.84%
Spyre Therapeutics
Nov 13, 2024
Maintains: Outperform
Price Target: $50 → $65
Current: $17.94
Upside: +262.32%
Apellis Pharmaceuticals
Nov 7, 2024
Maintains: Outperform
Price Target: $92 → $55
Current: $24.27
Upside: +126.62%
Mersana Therapeutics
Aug 14, 2024
Maintains: Neutral
Price Target: $4 → $3
Current: $0.38
Upside: +690.51%
Ocular Therapeutix
Aug 8, 2024
Maintains: Outperform
Price Target: $18 → $17
Current: $7.58
Upside: +124.27%
ORIC Pharmaceuticals
Mar 12, 2024
Reiterates: Outperform
Price Target: $27 → $25
Current: $6.14
Upside: +307.17%
Nuvalent
Feb 23, 2024
Initiates: Outperform
Price Target: $105
Current: $73.05
Upside: +43.74%
Aug 5, 2022
Maintains: Outperform
Price Target: $255 → $210
Current: $4.16
Upside: +4,948.08%
Apr 7, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $3.56
Upside: +855.06%
Nov 2, 2021
Initiates: Outperform
Price Target: $230
Current: $1.48
Upside: +15,440.54%